Although we cannot currently use therapies aimed at reducing Lp(a) in family members who have high Lp(a), since plasmapheresis is only indicated in patients with progressive cardiovascular disease and very high Lp(a), we can address the rest of the risk factors and reduce LDL levels, achieving the appropriate objectives based on their excess cardiovascular risk, as indicated by experts [14]. Here, LPA is linked to cardiovascular disorder.